FDA extends review of lung cancer treatment

SOUTH SAN FRANCISCO, Calif. The Food and Drug Administration has extended its review period for a lung cancer drug made by Genentech and OSI Pharmaceuticals, the two companies announced.

OSI submitted additional study data to support the companies’ regulatory approval application for Tarceva (erlotinib) as a first-line maintenance therapy for advanced non-small cell lung cancer, prompting the FDA to extend its review period by 90 days. The agency would have decided on whether to approve the drug on Monday, but will take until April.

Tarceva already has approval as a monotherapy in patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed after up to two courses of chemotherapy and as a treatment for pancreatic cancer, in combination with gemcitabine chemotherapy.

Poll

Poll

SPECIAL REPORTS

Are we in the midst of a beauty revolution? Perhaps. It is no secret that the ever-changing beauty category is all about trends, but one could argue that we are embarking on an especially interesting time in beauty as technology is changing the way consumers shop and new innovations strive to break through the noise.

In this beauty report, Drug Store News takes a deeper dive into some of the leading trends that are reshaping beauty.more ...

IN THIS ISSUE

In this issue, DSN examines PricewaterhouseCoopers' "Top Health Industry Issues for 2015;" takes you on a tour of Murad, shares beauty trends and insights and delves into location-based technology and how it is revolutionizing health, retail.Click here to view the issue.